A Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP6294 in the Treatment of Female Subjects with Bladder Pain Syndrome/Interstitial Cystitis, Trial ID 6294-CL-0101

Study summary

The purpose of this study is to investigate efficacy, safety and tolerability of ASP6294 in female participants with Bladder Pain Syndrome/Interstitial Cystitis (BPS/IC). This study will also investigate the pharmacokinetics (PK) and pharmacodynamics (PD) of ASP6294 in female participants with BPS/IC.

Additional Study Details

Phase

Product

N/A

Product

ASP6294

Placebo

Type

Interventional

Masking

Double (Participant, Investigator)

Enrollment number

119

Show Additional Study Details

Study documents

Scientific Results Summary

Available Language(s): English

Download Document(s)

Plain Language Summary

Available Language(s): English

Download Document(s)

Get more information

Would you like more information about clinical trial sites that are recruiting participants for A Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP6294 in the Treatment of Female Subjects with Bladder Pain Syndrome/Interstitial Cystitis? Contact us by filling out your information to the right and we’ll respond to you.

Requestor Information [I am…]

A caregiver
A healthcare provider
A parent
A patient
A patient advocate

First name

Last Name

Country/Region

Algeria
Argentina
Armenia
Australia
Austria
Belarus
Belgium
Bosnia And Herzegovina
Brazil
Bulgaria
Canada
Chile
China
Colombia
Croatia
Czech Republic
Denmark
Dominican Republic
Egypt
Estonia
Finland
Former Serbia and Montenegro
France
Georgia
Germany
Greece
Guatemala
Hong Kong
Hungary
Iceland
India
Indonesia
Ireland
Israel
Italy
Japan
Jordan
Kazakhstan
Latvia
Lebanon
Lithuania
Macedonia
Malaysia
Mexico
Montenegro
Morocco
Netherlands
New Zealand
Norway
Panama
Peru
Philippines
Poland
Portugal
Puerto Rico
Republic of Korea
Republic of Moldova
Romania
Russian Federation
Saudi Arabia
Serbia
Singapore
Slovakia
Slovenia
South Africa
Spain
Sweden
Switzerland
Taiwan, Province of China
Thailand
Turkey
Ukraine
United Kingdom
United States
Vietnam

By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

I give my consent to the processing of my personal data mentioned above according to Astellas Privacy Notice & Cookies Policy

Locations

Completed

Site NL31007

Sneek, Netherlands

Completed

Site PL48010

Warszawa, Poland

Withdrawn

Site ES34006

Barcelona, Spain

Completed

Site GB44006

Plymouth, United Kingdom

Completed

Site RU70006

St. Petersburg, Russian Federation

Completed

Site DE49007

Duisburg, Germany

Withdrawn

Site ES34005

La Cuesta, Spain

Completed

Site RU70002

St. Petersburg, Russian Federation

Completed

Site ES34007

Valencia, Spain

Completed

Site GB44002

Manchester, United Kingdom

Completed

Site LV37103

Daugavpils, Latvia

Withdrawn

Site DE49002

Nuertingen, Germany

Withdrawn

Site CZ42001

Kromeriz, Czech Republic

Withdrawn

Site HU36006

Gyor, Hungary

Completed

Site BE32001

Leuven, Belgium

Completed

Site LV37102

Riga, Latvia

Completed

Site PL48007

Wroclaw, Poland

Completed

Site PL48009

Lodz, Poland

Completed

Site RU70001

St. Petersburg, Russian Federation

Withdrawn

Site NL31005

Nijmegen, Netherlands

Withdrawn

Site GB44001

Glasgow, United Kingdom

Completed

Site HU36001

Csongrad, Hungary

Completed

Site LV37105

Riga, Latvia

Withdrawn

Site GB44004

Wrexham, United Kingdom

Completed

Site DE49001

Holzminden, Germany

Withdrawn

Site PL48001

Lublin, Poland

Withdrawn

Site CZ42003

Praha 4, Czech Republic

Withdrawn

Site NL31001

Rotterdam, Netherlands

Completed

Site ES34002

Malaga, Spain

Withdrawn

Site DE49011

Berlin, Germany

Withdrawn

Site PL48004

Chorzow, Poland

Completed

Site CZ42002

Plzen, Czech Republic

Completed

Site DE49005

Markkleeberg, Germany

Completed

Site LV37101

Riga, Latvia

Completed

Site HU36002

Budapest, Hungary

Completed

Site PL48002

Szczecin, Poland

Withdrawn

Site PL48006

Katowice, Poland

Withdrawn

Site PL48003

Bialystok, Poland

Completed

Site ES34001

Barcelona, Spain

Completed

Site ES34008

Madrid, Spain

Withdrawn

Site BE32002

Edegem, Czech Republic

Completed

Site RU70003

St. Petersburg, Russian Federation

Withdrawn

Site NL31002

Doetinchem, Netherlands

Withdrawn

Site DE49010

Monchengladbach, Germany

Completed

Site RU70008

St. Petersburg, Russian Federation

Completed

Site DE49003

Duisburg, Germany

Withdrawn

Site RU70005

Moscow, Russian Federation

Withdrawn

Site ES34003

Madrid, Spain

Trial info

Follow Trial

Age

18+ years

Condition

Bladder Pain Syndrome

Sex

Female

Trial Dates

Sep 2017 - Mar 2019

Share with

Additional Study Details

Inclusion Criteria

Subject’s signs, symptoms and diagnostic work-up are in accordance with the international society for the study of bladder pain syndrome (ESSIC) definition for bladder pain syndrome/interstitial cystitis (BPS/IC): pelvic pain, pressure or discomfort perceived to be related to the urinary bladder accompanied by at least 1 other urinary symptom such as persistent urge to void or frequency, for at least 6 months in absence of urinary infection or other obvious pathology or identifiable causes. There is documented proof of the diagnosis BPS/IC that has been entered into the subject’s records at least 2 months prior to Visit 1/Screening.
Subject has a score of ≥ 4 and ≤ 9 for pain as assessed by scoring the average pain of the week preceding Visit 1/Screening, using an 11-point NRS (0-10).
Subject has an estimated voiding frequency of ≥ 8 and ≤ 30 voids per 24 hours.
Subject has a score of ≥ 7 on the interstitial cystitis symptom index (ICSI) questionnaire.
Subject must either:
- Be of nonchildbearing potential:
- Postmenopausal (defined as at least 1 year without any menses for which there is no other obvious pathological or physiological cause) prior to screening, or
- Documented surgically sterile (e.g., hysterectomy, bilateral salpingectomy, bilateral oophorectomy)
- Or, if of childbearing potential,
- Agree not to try to become pregnant during the study and for 5 half-lives (i.e., 70 days) after the final study drug administration at Visit 5/Week 8, and
- Have a negative urine pregnancy test at Visit 1/Screening, and
- If heterosexually active, agree to consistently use 1 form of highly effective birth control starting at screening and throughout the study period and for 5 half-lives (i.e., 70 days) after the final study drug administration at Visit 5/Week 8.
Subject must agree not to breastfeed starting at screening and throughout the study period, and for 5 half-lives (i.e., 70 days) after the final study drug administration at Visit 5/Week 8.
Subject must agree not to donate ova starting at screening and throughout the study period, and for 5 half-lives (i.e., 70 days) after the final study drug administration at Visit 5/Week 8.
Subject must be willing and able to comply with study requirements (e.g., complete questionnaires and diaries, able to read and attend all required study visits).
Subject agrees not to participate in another interventional study while participating in the present study (i.e., between Visit 1/Screening and Visit 7/Week 18).
Subject has undergone at least 2 different therapies for BPS/IC with unsatisfactory results, prior to study entry.
Subject has at least moderate pain as reflected by an average MDP of ≥ 4.0 and ≤ 9.0. The average MDP is the average of daily assessments of MDP in the week prior to the visit with at least 5 recordings. Additionally, the MDP recordings must not differ over 4 points between consecutive days.
Subject has a mean voiding frequency of ≥ 8.0 and ≤ 30.0 per 24 hours as assessed with the 3 day electronic micturition diary in the week prior to the visit.
Subject is confirmed to be willing to comply and has shown to be compliant with all study requirements during the run-in period.

Exclusion Criteria

Subject has osteoarthritis or has a history of rapidly progressive osteoarthritis.
Subject has a score of ≥ 30 on the Pain Catastrophizing Scale (PCS).
Subject has a score of > 12 on the HADS-D (Hospital Anxiety and Depression Scale - Depression subscale).
Subject has significant pelvic floor pain or spasm which is considered the main cause of the chronic pelvic/bladder pain as concluded by the investigator based on the pelvic floor examination.
Subject has undergone a fulguration or excision of a Hunner’s lesion any time prior to the screening visit.
Subject has recently undergone or started treatment for BPS/IC as specified below:
- subject has undergone a cystoscopy with hydrodistension or Botox injections in the bladder within 6 months prior to the screening visit.
- subject has received non-pharmacological interventions for BPS/IC (including but not limited to electric stimulation therapy or acupuncture therapy) within 3 months prior to the screening visit.
- subject has received any intravesical pharmacological treatment for BPS/IC (including but not limited to heparin or dimethyl sulfoxide) within 4 weeks prior to the screening visit
- subject had an initiation, discontinuation, or variation in the dose and/or frequency of antimuscarinics, mirabegron, antidepressants (including amitriptyline), anticonvulsants, benzodiazepines, skeletal muscle relaxants, nonsteroidal anti-inflammatory drugs, non-opioid analgesics, pentosan polysulphate sodium, homeopathic medication and/or

herbal therapies during the last 4 weeks prior to the screening visit.

subject has had changes in non-pharmacological treatment for BPS/IC (e.g., diet or physical therapy) during the last 4 weeks prior to the screening visit.
Subject has bladder pathology as specified below:
- a post-void residual (PVR) >200 mL.
- subject has a known currently symptomatic urethral diverticulum.
- subject has genital tract condition or pelvic pathology (e.g., post-partum, post-pelvic surgery, post-hysterectomy) that may complicate diagnosis and the evaluation of pelvic pain and urinary symptoms. Note: A history of a Cesarean section is not a reason for exclusion.
- subject has a known currently symptomatic bladder or ureteral calculi.
- subject currently has cystitis (radiation cystitis, Bacillus Calmette-Guérin-induced cystitis, bacterial/tuberculous cystitis, cyclophosphamide cystitis) or has had a documented symptomatic bacterial cystitis within the last 1 month prior to the screening visit. In case of bacterial cystitis (UTI), the subject can be re-screened 1 month after successful treatment.
- subject has currently clinically significant urinary bladder abnormalities (e.g., bladder mass, bladder stone, bladder diverticulum, small contracted end-stage bladder), except for abnormalities associated with BPS/IC.
- subject has had any invasive procedures of either the urinary bladder, urethra, ureter or renal pelvis (e.g., transurethral resection of bladder [including bladder biopsy], urethral dilatation, endovesicular lithotripsy) within 3 months prior to the screening visit.
- subject has a known current neurologic disease or a defect affecting urinary bladder function (e.g., neurogenic bladder, systemic or central neurological disease, such as Multiple Sclerosis or Parkinson’s disease).
- subject has a known current lower urinary tract malignancy. In case of positive sediment (micro) hematuria results, local procedures/guidelines will need to be followed to exclude malignancy. Only if hematuria has been present within the last 6 months and malignancy has been adequately ruled out by the investigator according to local diagnostic procedures, the subject does not have to be excluded. Note that if the subject had a (negative) bladder biopsy, the subject can only be re-screened after 3 months following this biopsy. Documentation of all diagnostic outcomes and investigator’s decisions need to be available.
Subject has a known history of, or currently has inflammatory bowel disease (i.e., Crohn’s Disease or Ulcerative Colitis) and/or Sjögren Syndrome.
Subject has a known current severe constipation and/or severe diarrhea, severe active diverticulitis and/or severe gastrointestinal bleeding.
Subject has a known or suspected hypersensitivity to ASP6294 or any components of the formulation used.
Subject has been pregnant within 6 months prior to screening assessment or breast feeding within 3 months prior to screening.
Subject has a known history of an allergic or anaphylactic reaction to biological drugs (e.g., [monoclonal] antibodies including tanezumab or fusion proteins).
Subject has received a biological drug (e.g. [monoclonal] antibodies including tanezumab or fusion proteins) during the last 6 months prior to the screening visit.
Subject has a known history of hepatitis B or C or human immunodeficiency virus (HIV) infection.
Subject has a known history of or has a currently active or treated sexually transmittable disease (including genital herpes).
Subject has a known current substance abuse issue (including alcoholism).
Subject has peripheral neuropathy, or an abnormality has been observed during the sensory testing at Visit 1/Screening.
Subject has a known currently clinically severe, unstable or uncontrolled renal, hepatic, respiratory, hematological, genitourinary (except BPS/IC), cardiovascular, endocrine, neurological, psychiatric, or other medical illness that may put the subject at safety risk or may mask measures of efficacy.
Subject has had any malignancy diagnosed within 5 years prior to the screening visit, except for curative treated localized non-melanoma skin cancer (e.g. basal cell or squamous cell carcinoma).
Subject has a known current psychiatric condition, mental incapacity, language barrier or the inability to read that would impair the subject’s successful participation in the study.
Subject has a body mass index of ≥ 40 kg/m^2 as sign of morbid obesity.
Subject has any condition that makes the subject unsuitable for study participation.
Subject has received investigational therapy (i.e., not yet approved experimental medicine) within 28 days or 5 half-lives, whichever is longer, prior to the screening visit.
Subject is an employee of the Astellas Group, the Contract Research Organization (CRO) involved, or the investigator site executing the study.
Results of the Visit 1/Screening blood sample indicate that the subject has active hepatic and/or biliary disease, defined as: liver enzymes aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 2 times the upper limit of normal (ULN), or total bilirubin (TBL) > 1.5 times the ULN.
Result of the Visit 1/Screening serum pregnancy test is positive.
Results of the Visit 1/Screening blood/urine samples indicate that the subject has clinically significant abnormal biochemistry, hematology or urinalysis safety laboratory values.

Frequently Asked Questions

Are clinical trials only for people with advanced cancer?

While some clinical trials may focus on more advanced cancers, many trials are open to patients at various stages of their cancer. Each study has rules about who can take part. For example, only patients in a certain age group or those who have a certain type of tumor may be able to join.

Will I have to stop my current treatment to participate in a clinical trial?

Sometimes researchers want participants to keep taking their current treatments during a clinical trial. Other times, you may need to stop your current treatments for a while. If the investigational treatment doesn't work, you can usually go back to your original treatment plan.

Should I be worried about getting a placebo?

In cancer clinical trials, a placebo is only used if there is no other treatment for that type of cancer. This helps compare an investigational treatment to the placebo. Placebos are rarely used in cancer trials because the best available treatment, called the “standard of care”, is usually given instead.

Do I need a referral from my doctor to take part in a study?

Your doctor may not know about all the opportunities for clinical trials that are available to you. Talk to your doctor or other medical provider about clinical trial information that you find. They can help you decide if a clinical trial is right for you. If you do not find any options on this website, we recommend you visit an online public registry website like clinicaltrials.gov to see a wide variety of available clinical trials.

Explore More

A Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP6294 in the Treatment of Female Subjects with Bladder Pain Syndrome/Interstitial Cystitis

Study summary

Additional Study Details

Study documents

Get more information

Locations

Frequently Asked Questions

Explore More

What are clinical trials?

Why are Clinical Trials Important?

Why Participate in a Clinical Trial?